Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. boosted its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 35.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,078,852 shares of the company’s stock after acquiring an additional 280,390 shares during the period. Epoch Investment Partners Inc. owned about 2.21% of Amphastar Pharmaceuticals worth $43,154,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Amphastar Pharmaceuticals by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 2,815,596 shares of the company’s stock valued at $174,145,000 after purchasing an additional 48,203 shares during the last quarter. TD Asset Management Inc boosted its stake in Amphastar Pharmaceuticals by 67.4% in the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock worth $67,663,000 after buying an additional 680,976 shares during the last quarter. American Century Companies Inc. grew its holdings in Amphastar Pharmaceuticals by 19.7% in the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock valued at $29,616,000 after buying an additional 121,764 shares during the period. Boone Capital Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the 4th quarter valued at about $24,740,000. Finally, Granite Investment Partners LLC increased its stake in shares of Amphastar Pharmaceuticals by 12.7% during the 2nd quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock valued at $15,901,000 after acquiring an additional 44,744 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMPH has been the subject of a number of recent analyst reports. Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. StockNews.com upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now owns 75,409 shares in the company, valued at $3,504,256.23. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the sale, the director now directly owns 75,409 shares in the company, valued at approximately $3,504,256.23. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO William J. Peters sold 3,596 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total value of $147,184.28. Following the completion of the transaction, the chief financial officer now owns 94,103 shares of the company’s stock, valued at approximately $3,851,635.79. The disclosure for this sale can be found here. In the last three months, insiders sold 37,979 shares of company stock worth $1,671,307. Corporate insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 1.8 %

AMPH opened at $49.18 on Monday. The company has a market cap of $2.41 billion, a PE ratio of 17.02, a price-to-earnings-growth ratio of 0.85 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The firm has a 50 day moving average price of $44.56 and a 200 day moving average price of $42.61.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.10. The company had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. Sell-side analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.